Winayak, R., Qi, X., Moradi, A., Ebrahimi, H., Gomes, A. C., Zugman, M., Jaime-Casas, S., Li, X., Dorff, T. B., Hsu, J., Chehrazi-Raffle, A., Takahashi, M., Oka, K., Higashi, S., Lee, P. P., Parks, T. P., Karmouch, J., Jenq, R. R., Pal, S. K., Dizman, N. (2026). Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade (ICB)–based first line therapies in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4519